Abstract:This paper studies novel techniques for synthesizing 3‐Amino‐5,6‐Dimethyl‐l,2,4‐triazine, and new l,2,4‐triazine derivatives under free solvent conditions. All the target compounds were synthesized in accepTable quantities. Furthermore, NCI selected some of the synthesized compounds to test for potential in vitro anticancer activity against a panel of sixty human cancer cell lines covering nine tumor panels. Two effective one‐pot synthesis procedures were proposed for the synthesis of 3‐amino‐5,6‐dimethyl‐l,2,4‐triazine under free solvent conditions; these methods included fusing the monohydrazide of biacetyl with either methyl carbamimidothioate (Method B) or cyanamide (Method C). Simple reaction conditions, an easy work‐up process, and facile separation characterize the ecologically friendly fusion process used in techniques B and C. The results from methods B and C indicated the existence of amino‐imino prototropic tautomerism. The triazine in method C had a different melting point and had unusual mass spectral behavior, suggesting that it was in the imino‐tautomer form, as opposed to the amino‐tautomer form discovered in procedure B. The strong electron‐withdrawing activity of the triazine ring appears to deactivate the 3‐amino group, which in turn triggers the production of additional triazine derivatives (3–12), with yields ranging from 54% to 82%. To characterize the structure of the newly synthesized compounds, 1H, 13C‐NMR, and mass spectrometry were employed. The compounds that were created underwent testing at the National Cancer Institute. According to the screening results, conjugates 9 and 10 were successful against most of the cancer cell line subpanels. With the use of DFT, we conducted theoretical studies on compounds 9 and 10. Topological studies, including ELF, LOL, and RDG, were used to identify the main binding sites and weak interactions of the target derivatives. The synthesized compounds that have promising properties are subjected to a pharmacological examination using Swiss‐ADME. Cox‐1 (PDB ID: 3KK6) is the target of molecular docking experiments that aim to identify the anticancer active site of the derivatives of interest.

Antitumor Activity of s-Triazine Derivatives: A Systematic Review

Recent Advances in the Biological Activity of s-Triazine Core Compounds

Recent Updates on 1,2,3‐, 1,2,4‐, and 1,3,5‐triazine Hybrids (2017–present): the Anticancer Activity, Structure–activity Relationships, and Mechanisms of Action

1,3,5-Triazine as a promising scaffold in the development of therapeutic agents against breast cancer

Synthesis and Antitumor Activity of 2-Aryl-1, 2, 4-Triazolo[1, 5-A] Pyridine Derivatives

Exploring the Anticancer Potential of Triazine Derivatives: An Outlook of Designing Strategies, Docking Studies, and Structure‐Activity Relationships (SAR)

Synthesis and Reactions of 3‐Amino‐5,6‐Dimethyl‐l,2,4‐Triazine: DFT Studies, ADME Assay, and Molecular Docking on the new l,2,4‐Triazine Derivatives as Anticancer Agents.

1,2,3‐Triazole hybrids as anticancer agents: A review

Structural modification strategies of triazoles in anticancer drug development

s-Triazine: A Privileged Structure for Drug Discovery and Bioconjugation

The Anticancer Action of a Novel 1,2,4-Triazine Sulfonamide Derivative in Colon Cancer Cells

New 3-[(4-hydroxy-6-methly-2(1h)-pyridinones)-3-yl]-4-substituted-(1h)1,2,4- Triazole-5-Thiones: Efficient Synthesis, X-Ray Crystallographic Analysis, and Antitumor Activity

1,3,5-Triazine: Recent Development in Synthesis of its Analogs and Biological Profile

Targeted synthesis via the structure-activity relationship: Biological evaluation of new 1,2,3-triazoles monoterpene as antitumor agents

Parallel Synthesis of Novel Antitumor Agents: 1,2,3-Triazoles Bearing Biologically Active Sulfonamide Moiety and Their 3D-QSAR

Syntheses, Molecular Targets and Antitumor Activities of Novel Triptycene Bisquinones and 1,4-Anthracenedione Analogs

Synthesis and Anticancer Activity Evaluation of a Series of [1,2,4]Triazolo[1,5-A]pyridinylpyridines in Vitro and in Vivo

Solid-phase synthesis and antitumor evaluation of 2,4-diamino-6-aryl-1,3,5-triazines.

Recent Advances in the Development of Pyrazole Derivatives as Anticancer Agents

Green Approach Toward Triazole Forming Reactions for Developing Anticancer Drugs

2-Aminobenzothiazoles in anticancer drug design and discovery